https://librepathology.org/w/index.php?action=history&feed=atom&title=CAP_Molecular_Diagnosis_of_Lung_Cancer 2026-09-12T18:46:55Z Revision history for this page on the wiki MediaWiki 1.43.9 https://librepathology.org/w/index.php?title=CAP_Molecular_Diagnosis_of_Lung_Cancer&diff=39156&oldid=prev 2015-08-12T13:27:38Z

<p>Created page with &quot; {{hidden|List 5 treatment defining molecular transformation, the neoplasm, and the genetic alteration|1. 100% of CML: BRR-ABL &gt; Imatinib, 2. 20% of Lung Adenocarcinoma: EGFR...&quot;</p> <p><b>New page</b></p><div><br /> {{hidden|List 5 treatment defining molecular transformation, the neoplasm, and the genetic alteration|1. 100% of CML: BRR-ABL &gt; Imatinib, 2. 20% of Lung Adenocarcinoma: EGFR &gt; Erlotinib/Gefitinib, 3. 25% Infiltrative ductal carcinoma of breast HER2&gt;Trastuzumab, 4. 50% of Melanoma, BRAF v600E &gt; PLX4032, 5. 4% of Lung Adenocarcinoma: ALK &gt; Crizotinib}}<br /> <br /> {{hidden|List and describe 5 areas of Genetic characaterization of tumours for personalized medicine|DNA mutations, DNA chromosomal alterations, mRNA and MiRNA profiling, Proteomics, DNA epigenetics}}<br /> <br /> {{hidden|What fraction of Lung adenocarcinomas have no known detactable mutations|42%}}<br /> <br /> {{hidden|What are the three most common molecular alterations of Lung Adenocarcinoma|KRAS 23%, EGFR 15%, TP53 5%}}<br /> <br /> {{hidden|What is the two most common molecular alteration makes patients with EGFR mutations resistant to targetted therapies?|KRAS (primary) and T790M (primary and acquired)}}<br /> <br /> {{hidden|List two EGFR kinase inhibitors.|Gefitinib/Iressa, Erlotinib/Tarceva}}<br /> <br /> {{hidden|What are the three most common cancers associated with KRAS mutations?|Pancreatic 90%, Colon 50%, Lung NSCLC 30%}}<br /> <br /> {{hidden|Why don&#039;t KRAS + tumours respond to Anti EGFR therapies?|KRAS is downstream from EGFR, so changing the function of EFGR would not have any effect on mutated KRAS}}<br /> <br /> {{hidden|Explain the cost effectiveness of genetic testing for targetted therapies?|Most molecular tests cost $200-1000, vs one month of targetted therapy $2000-10000/month}}<br /> <br /> {{hidden|What are the three most common cancers associated with BRAF mutations?|Melanoma 70%, Papillary Thyroid Carcinoma 50%, Ovarian serious carcinoma 30%, Colon cancer 10%, Hint Papillary architecture}}<br /> <br /> {{hidden|Beta catenin/CTNNB1 expression is found with which histological pattern of lung adenocarcinoma?|Low grade adenocarcinoma of fetal type, poor px, &lt;40yo, and has glycogen rich glandular formations, may occur in FAP patients}}<br /> <br /> {{hidden|What is the most common ALK rearrangement found in NSCLC?|EML4-ALK (90% of the 13% of lung cancers found to due to ALK fusions)}}<br /> <br /> {{hidden|List some pros and cons of ALK FISH.|Pros: commercial FDA approved probes available, not too expensive, moderately easy to disseminate screening, clinically validated, and failed tests on poorly preserved tissues are not reported as negative. Cons: need fish lab expertise (including pathologist and PhD), can be tricky if genes are close}}<br /> <br /> {{hidden|List some pros and cons of ALK IHC.|Pros: fast, cheap, easy to disseminate screening, Cons: commercial antibodies sub-optimal, poorly preserved tissues (esp bx) may give false negative results due to loss of antigenicity, no internal control}}<br /> <br /> {{hidden|What is a positive count in the ALK-FISH?|Signal split &gt;2 probe diameters}}</div>

Tate